Refine by
Small Molecule Targeted Drug Articles & Analysis: Older
80 news found
This iterative process facilitates the creation of drug candidates that not only show promise in early trials but are also more likely to advance through the rigorous drug development pipeline. ...
Another innovative service by CD Formulation is the development of Radionuclide Drug Conjugates (RDCs). These unique formulations combine targeting ligands with radioisotopes, providing dual functionalities of imaging and therapeutic action. RDCs leverage medical radionuclides to integrate treatment modalities with diagnostic capabilities, augmenting personalized ...
Ace Therapeutics is a preclinical contract research provider engaged in metabolic disorders, infectious diseases and parasites, neurological disorders, ophthalmic diseases, gastrointestinal disorders, and immune system diseases. Following with the announcement of developing small molecule drug for glaucoma, Ace Therapeutics recently unveiled disease model customization services to accelerate ...
Alfa Cytology, a premier contract research organization, recently launched its full-scale pancreatic cancer research services with robust platforms, powerful analytics, and cross-platform collaborations. Pancreatic cancer (PC) is a severe disease that is difficult to diagnose in the early stages due to its complex and hidden nature. Studies found that the incidence rate of PC has been ...
Small molecules play a crucial role in modern drug discovery and development. ...
These microneedles are composed of a biocompatible material that dissolves upon insertion, allowing for controlled and targeted drug release. The dissolving microneedle preparation services offered by CD Formulation provide a comprehensive solution for pharmaceutical companies looking to optimize drug delivery. ...
Customization for Personalized Medicine: Antibodies are tailored to individual patient profiles, enhancing the potential for personalized medicine and increasing treatment efficacy while minimizing side effects. 5. Integration with Protein Drug Design: CD ComputaBio's platform seamlessly integrates Antibody De Novo Design with Protein Drug Design, ...
This critical step in the drug development process refers to the systematic evaluation of the safety of therapeutic drugs through laboratory studies and animals in vitro. ...
Creative Diagnostics, a global leader in providing raw materials, antibodies, and reagents for the biotechnology industry, recently introduced comprehensive contract ELISA kit development services to the R&D and IVD communities, facilitating regulatory approval submissions. With expertise in antibody generation and immunoassay development, Creative Diagnostics can generate various diagnostic ...
The company is pleased to announce the launch of the Protein-Small Molecule Docking service, designed to help customers quickly and accurately design and screen drugs. ...
The vgAAV vector platform, based on novel engineered AAV capsids, enables a superior transduction of target cells and is designed to efficiently cross biological barriers. ...
With Vividion and its industry-leading chemoproteomics platform, Bayer made a significant investment to magnify its small molecule drug discovery capabilities and pipeline of precision therapeutics. Vividion’s breakthrough technology can unlock high value, traditionally undruggable targets of the human disease proteome. ...
ByBayer AG
About Proteros biostructures GmbH Proteros is a privately-held company with expertise in structure-based drug discovery powered by a cutting-edge discovery engine tailored to unlock even the most technically challenging disease-relevant drug targets. The company provides small molecule drug ...
PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, ...
Appropriate drug formulation is a prerequisite for successful drug development. CD Formulation, a highly specialized CRO service provider, recently announced its capability of offering one-stop pharmaceutical formulation solutions that can make drug development faster, easier, and more cost-effective. Drug formulation, or pharmaceutical formulation, is a universal challenge faced by biotech ...
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today provided an update on the status of multiple clinical trials now underway to assess the safety and efficacy of TPOXX to treat monkeypox. In recent weeks, randomized, placebo-controlled clinical trials were initiated in ...
Under the terms of the agreement, Terray and Calico will identify small molecule leads against a set of targets nominated by Calico using the Terray tNova platform, with Calico subsequently assuming responsibility for development and commercialization. ...
” “Despite decades of effort, many targets remain inaccessible to traditional small molecule drugs, and many others have uncertain relevance to disease,” said Vividion Therapeutics CEO Jeffrey Hatfield. ...
ByBayer AG
Recent advances in the architecture and scale of AI are leading us from the era of narrowly focused AI (e.g. text auto-complete, immune epitope prediction in a protein sequence, antibody domain detection) to broader models with applications across domains from sales and marketing to medical diagnostics. In protein biochemistry these are the “AIFold” models such as AlphaFold2, ...
(“Aesther”) (NASDAQ: AEHA) recently announced business combination, once closed, will further Ocean Biomedical’s work on the discovery of a whole new class of antimalarial drugs which target PfGARP and kill malaria parasites. In recent studies published and reviewed in Nature, Ocean Biomedical’s Scientific Co-founder, Dr. ...